Adheren, Inc. is a biotechnology company focusing on cancer immunotherapy. We have developed our core technology platform, antibody cell conjugation (ACCTM), to attach antibodies directly to immune cells, such as T cells. Using this methodology, we have initiated an anti-cancer T cell therapy approach, called T-PICKTM (T cell proximity induced cell killing). T-PICK has been validated both in vitro and in vivo, providing compelling new avenues for the treatment of a variety of cancer types. We are currently partnering with a major university to validate the use of T-PICK technology in human clinical trials.
Relative to other cell-based immunotherapy approaches, T-PICK technology requires no genetic engineering of the T cells and has a substantially improved dose-titration capability. In addition, the T-PICK approach is readily compatible with any antibody under development.
Website is currently under construction. Please contact firstname.lastname@example.org for more information.
For ordering research tool products, please visit shop.adheren.com